Cara Therapeutics | CARA - Cash And Equivalent

Stock Price
3.39
Daily Change
0.17 5.28%
Monthly
-1.45%
Yearly
-80.60%
Q2 Forecast
2.82

Cara Therapeutics reported $21.42M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Assertio Holdings USD 38.5M 8.59M Sep/2025
Cara Therapeutics USD 21.42M 770K Sep/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Chugai Pharma JPY 456.43B 40.66B Sep/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Pacira USD 158.54M 10.96M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025